ValuEngine Upgrades Genomic Health (GHDX) to “Hold”
Genomic Health (NASDAQ:GHDX) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.
GHDX has been the subject of a number of other reports. Zacks Investment Research raised Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. Cowen reaffirmed a “hold” rating and issued a $34.00 target price on shares of Genomic Health in a research report on Friday, September 1st. Jefferies Group reaffirmed a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a research report on Thursday, September 14th. Canaccord Genuity reaffirmed a “buy” rating and issued a $39.00 target price on shares of Genomic Health in a research report on Wednesday, November 15th. Finally, BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $31.57.
Shares of Genomic Health (NASDAQ:GHDX) opened at $33.28 on Friday. Genomic Health has a 52-week low of $26.37 and a 52-week high of $34.18.
In other news, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $31.47, for a total value of $157,350.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,379 shares of company stock valued at $511,531. 46.20% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio purchased a new position in shares of Genomic Health in the 3rd quarter valued at about $444,000. GSA Capital Partners LLP boosted its stake in shares of Genomic Health by 43.7% in the 3rd quarter. GSA Capital Partners LLP now owns 63,100 shares of the medical research company’s stock valued at $2,025,000 after buying an additional 19,200 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Genomic Health in the 3rd quarter valued at about $138,000. Point72 Asset Management L.P. purchased a new position in shares of Genomic Health in the 3rd quarter valued at about $350,000. Finally, Jane Street Group LLC purchased a new position in shares of Genomic Health in the 3rd quarter valued at about $227,000. Institutional investors and hedge funds own 89.76% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/12/14/valuengine-upgrades-genomic-health-ghdx-to-hold.html.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.